Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMB-09 in advanced solid tumors
NCT05263180Phase 1Recruiting
- Sponsor
- EpimAb Biotherapeutics
- Start
- Jul 2022
- Primary completion
- Dec 2023
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of EMB-09 in solid tumor, sponsored by EpimAb Biotherapeutics. Primary endpoints: Incidence and severity of adverse events, Incidence of serious adverse events (SAE) and 3 more. Started Jul 2022; status: recruiting.
02
Drugs
EMB-09
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05263180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05263180.